Semax: the ACTH fragment engineered to sit still

Semax is a synthetic heptapeptide that takes a fragment of a natural signalling molecule and makes it last longer. Its core is ACTH(4-7), the Met-Glu-His-Phe stretch of adrenocorticotropic hormone, capped at the C-terminus with a Pro-Gly-Pro tail. That Pro-Gly-Pro addition is the whole trick: the three extra residues slow the peptidases that would otherwise cleave the fragment within minutes, so the active core survives long enough to be studied in living systems. The result is a small, stable molecule that carries the behavioural and neurotrophic character associated with short ACTH fragments while shedding the hormone's steroid-releasing function. It is a linear chain of standard amino acids, which is why it can be drawn as a simple residue sequence.

The peptide was developed in Russia, at the Institute of Molecular Genetics of the Russian Academy of Sciences together with Moscow State University, during the late Soviet period. It grew out of a broader program on short ACTH-derived peptides that set out to separate the hormone's effects on attention, memory and neuronal protection from its role in driving corticosteroid release. Semax has since been used in Russian neuroscience for decades and appears in a large domestic literature covering everything from experimental stroke models to studies of attention. Far less of that work, however, has been reproduced in laboratories outside Russia, which is a recurring theme with this whole family of peptides and a fact worth keeping in mind when weighing the strength of any individual claim.

Mechanistically, Semax is studied as a melanocortin-related and neurotrophic peptide. The most consistent finding across rodent studies is that it raises levels of brain-derived neurotrophic factor (BDNF) and its receptor TrkB in regions such as the hippocampus and basal forebrain, and modulates the downstream signalling those receptors control. Other lines of work report interaction with the dopaminergic and serotonergic systems, shifts in the expression of genes tied to inflammation and vascular biology after experimental brain ischaemia, and inhibition of enkephalin-degrading enzymes, an action that would prolong the presence of the nervous system's own regulatory peptides. Taken together these reports sketch a compound that nudges several signalling systems at once rather than flipping a single molecular switch, which is both its appeal and the source of much of the uncertainty around it.

The published record centres on the central nervous system. Investigators have looked at experimental cerebral ischaemia, cognitive performance in rodents, attention and adaptive behaviour under stress, and cellular markers of neuronal protection and oxidative stress. Genome-wide expression studies have been used to map which transcripts shift after the peptide is applied, an approach that suits a molecule whose effects appear broad rather than tied to one receptor. A parallel strand examines Semax as a modulator of the inflammatory response in nervous tissue, including the suppression of proinflammatory mediators in models of reversible brain injury. The common thread is that the interesting readouts are almost always functional or transcriptional rather than the clean receptor-binding curves you would expect from a classic single-target drug.

Structurally the molecule is a linear chain of seven standard L-amino acids with free termini, which is why it is represented by its residue sequence rather than a small-molecule structure. A more heavily modified relative, N-acetyl Semax amidate, caps both ends of the same backbone to resist peptidases for even longer, and it is sometimes studied as a longer-lived alternative. The plain heptapeptide, though, remains the reference form in most of the literature and is the version whose verified formula and mass are listed below. Because the sequence is entirely standard residues, the molecule can be identified and quality-checked against well-defined analytical benchmarks, which matters for any research supply that needs to confirm it has the right compound in the vial.

The caveats are real and worth stating plainly. The great majority of Semax studies come from a small number of Russian groups and are published in Russian-language journals, so independent replication outside that ecosystem is thin. Many reports are short, use small animal cohorts, and describe effects that are statistically modest. The mechanistic story, a peptide that gently raises BDNF and touches several neurotransmitter systems, is plausible but loosely specified: without a clean primary receptor, cause and effect are hard to pin down and easy to overstate. Read the mechanism as a working model rather than a settled account, and read the more dramatic claims that circulate online with corresponding skepticism. As a research tool the peptide is interesting; as a finished story it is not.

For laboratory research use only. Not for human or veterinary use.

Verified molecule

• Sequence: MEHFPGP (ACTH(4-7) core Met-Glu-His-Phe, extended with Pro-Gly-Pro)
• Molecular formula: C37H51N9O10S
• Molecular weight: 813.9 g/mol
• CAS number: 80714-61-0

Common questions

What is the Pro-Gly-Pro tail for?

It is a stability cap. The three residues added at the C-terminus slow enzymatic breakdown of the peptide, so the ACTH(4-7) core stays intact long enough to act in experimental systems. The native fragment on its own is degraded almost immediately, which makes it useless as a research probe. The tail solves that problem without adding a new active site of its own.

Does Semax behave like ACTH?

Only in part. It is derived from ACTH, but the fragment it is built on lacks the region that drives corticosteroid release, so research frames it as a melanocortin-related, neurotrophic-signalling peptide rather than a substitute for the full hormone. In practice its studied effects sit on the neuronal and behavioural side of ACTH biology, not the endocrine side.

How strong is the evidence base?

Most of it is preclinical and heavily concentrated in the Russian groups that developed the compound, with limited independent replication elsewhere. That does not make the findings wrong, but it does mean the peptide is best regarded as a research tool whose mechanism is still being characterised, not as something with a settled, widely reproduced profile.

References

1. The peptide ACTH(4-7)PGP (Semax) suppresses proinflammatory mediators after reversible brain ischemia. Molekuliarnaia Biologiia, 2021.
2. Dolotov OV, et al. Semax, an analogue of ACTH(4-10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain. Journal of Neurochemistry, 2006.